Introduction {#Sec1}
============

Knee osteoarthritis (OA) is a degenerative joint disease associated with chronic pain, resulting in reduced health-related quality of life (HRQoL) compared with healthy individuals, and a high rate of disability \[[@CR1]--[@CR3]\]. Approximately 30 million adults in the USA have OA and at least 19% of individuals over the age of 45 are affected by knee OA \[[@CR2], [@CR4]\]. There is no cure for OA, but there are pharmacologic treatment options available to reduce pain, including intra-articular (IA) injections of corticosteroids and local anesthetics \[[@CR5]--[@CR8]\].

IA administration of local anesthetic is used primarily during or after knee arthroscopy, but has also been used for the short-term pain management of knee OA and to aid in the diagnosis of local versus referred pain \[[@CR6], [@CR9]\]. Commonly used local anesthetics include lidocaine, bupivacaine, ropivacaine, and procaine \[[@CR6]\]. Local anesthetic injection is associated with rapid onset of analgesia; however, rapid absorption, distribution, and clearance from the injection site result in a short duration of pain relief (\~ 4 h) thereby limiting the use of local anesthetics in the management of chronic OA pain \[[@CR6], [@CR10]--[@CR14]\]. The addition of a vasoconstrictor, such as epinephrine, can increase the duration of local anesthesia, but is contraindicated for use in IA injections \[[@CR6], [@CR15]\]. The rapid onset of analgesia provided by local anesthetics makes them ideal candidates for combination with slower onset but longer-acting IA injection drugs, such as corticosteroids.

Corticosteroids used for the treatment of OA include dexamethasone, betamethasone, methylprednisolone, and triamcinolone acetonide (TA) \[[@CR9], [@CR16]\]. Corticosteroids are prepared as solutions or crystalline suspensions, with the most commonly used corticosteroids for IA injections being the crystalline suspension of TA and the solution formulations of prednisolone and methylprednisolone \[[@CR16]\]. IA corticosteroids such as TA are used extensively for the treatment of knee OA and are commonly combined with local anesthetics in clinical practice \[[@CR7]--[@CR9]\].

Addition of local anesthetics to corticosteroid for IA injection provides rapid pain relief \[[@CR6], [@CR17]--[@CR19]\]. The rapid onset of analgesia is useful for reducing periprocedural discomfort and, in certain situations, can help clinicians differentiate local and referred joint pain \[[@CR6], [@CR9], [@CR17]\]. The volume of local anesthetic used varies between physicians, with typical IA knee injection volumes of between 5 mL and 10 mL of combined local anesthetic and corticosteroid mixture \[[@CR7], [@CR9], [@CR16], [@CR20]--[@CR22]\]. In a survey of 506 rheumatologists, 65.9% reported that they combine local anesthetic in the syringe with corticosteroid when injecting the knee \[[@CR23]\]. The most common reasons provided by physicians for combining local anesthetic with corticosteroids prior to injection were to provide immediate pain relief, to dilute or increase volume of steroid preparation, and to decrease post-injection flare \[[@CR23]\]. Multiple previous studies have established the compatibility of standard corticosteroids mixed with local anesthetic and these combinations are frequently used in clinical studies, with the choice of local anesthetic and corticosteroid used for injection determined by clinical preference \[[@CR6], [@CR7], [@CR16], [@CR19]--[@CR22], [@CR24]--[@CR26]\].

Triamcinolone acetonide extended-release (TA-ER) is a novel formulation of TA in poly (lactic-*co*-glycolic acid) microspheres, which maintains prolonged concentrations of TA in the joint compared to standard TA crystalline suspension (TAcs) \[[@CR27]\]. TA-ER 32 mg, in a standard, approved injection volume of 5 mL, has demonstrated rapid, substantial, and durable pain relief in patients with knee OA \[[@CR28]--[@CR30]\]. To provide patients with analgesia during and immediately following IA injections, clinicians may desire to add local anesthetic to TA-ER injection solutions. As there is currently no data available in the literature regarding the suitability of combining TA-ER and local anesthetics, it is necessary to perform studies evaluating the compatibility of TA-ER and local anesthetic mixtures \[[@CR31]\]. Because local anesthetics are rapidly distributed and cleared from the injection site, and since prior studies have established the compatibility of local anesthetics and corticosteroids in vitro and in vivo, the present study evaluated the impact of mixing lidocaine, ropivacaine, and/or bupivacaine on the chemical and physical properties of TA-ER prior to intra-articular injection.

Methods {#Sec2}
=======

Sample Preparation {#Sec3}
------------------

In this compatibility study the local anesthetics mixed with TA-ER (32 mg) were lidocaine hydrochloride solution (1%; Hospira, San Jose, California, USA), bupivacaine hydrochloride solution (0.25%; Hospira, San Jose, California, USA), and ropivacaine hydrochloride solution (0.5%; Fresenius Kabi USA, Lake Zurich, Illinois, USA).

The TA-ER suspensions were prepared as described in the marketed product instructions for use, with the full contents of each 32 mg TA-ER vial being dispersed in 5 mL of TA-ER diluent \[[@CR32]\]. TA-ER diluent is an aqueous diluent of pH between 4.5 and 7.5 containing normal saline for tonicity and a small amount of surfactant to aid in product wetting and dispersion. Six product suspension combinations were tested: (i) 5 mL TA-ER suspension "undiluted" (control); (ii) 5 mL TA-ER suspension and 5 mL (additional) TA-ER diluent; (iii) 5 mL TA-ER suspension and 5 mL lidocaine; (iv) 5 mL TA-ER suspension and 5 mL bupivacaine (v) 5 mL TA-ER suspension and 5 mL ropivacaine; and (vi) 5 mL TA-ER suspension and 2 mL lidocaine, 1.5 mL bupivacaine, and 1.5 mL ropivacaine.

The suspension combinations were prepared by drawing a full dose (5 mL) of reconstituted TA-ER into a 10-mL syringe followed by drawing 5 mL of local anesthetic or diluent. Once combined, the syringe contents were mixed by multiple inversions and stored for 30 min at ambient room temperature. Prior to analysis, the syringe contents were re-mixed by inversion to re-establish a homogenous suspension.

Mixtures were freshly prepared in triplicate. Syringeability, pH, particle size, and optical microscopy were assessed using one set of triplicate preparations, with high-performance liquid chromatography (HPLC) analysis of purity and percentage free drug assessed using a separate set of triplicate preparations.

Syringeability and pH Assays {#Sec4}
----------------------------

After the product mixtures had been stored for 30 min and then remixed, any residual air or foam that could result from mixing of the solution performed more vigorously than a gentle swirl was ejected from the product needle and a new 21-gauge × 1.5-inch needle was attached to the syringe. Once again, the syringe was inverted to ensure the contents were well mixed. With firm and constant pressure applied by the thumb to the plunger, the contents of the syringe were injected into a scintillation vial to be used for pH measurement. Clogs were defined as the complete stoppage of the flow of suspension through the needle. A clog during injection was recorded as a failure and results were recorded as pass/fail.

Following this syringeability test, the pH of the sample preparations (\~ 25 °C) was tested using a calibrated pH meter (Orion STAR, A214). Each sample was measured in duplicate, and the average of the two readings was used to calculate the reported mean for each preparation. A total of three preparations were used to determine the mean response and standard deviation (*n* = 3).

High-Performance Liquid Chromatography {#Sec5}
--------------------------------------

Drug purity and percentage free drug were measured using a proprietary validated reversed-phase gradient HPLC method. The chromatographic equipment used was an Agilent 1260 series instrument with diode array UV detection. The HPLC instrument was fitted with a functionalized mixed-mode C18 column (150 mm × 4.6 mm, particle size 3 µm). The injection volume was 20 µL.

Standard solutions of TA (USP, Rockville, Maryland, USA) were prepared in dimethyl sulfoxide (DMSO) with subsequent dilution in a water/acetonitrile/formic acid HPLC diluent to achieve a final TA concentration of 0.2 mg/mL.

Samples were prepared by harvesting drug product particles using centrifuge filtration. The filtrate was collected and dried at 30 °C for 1 h, with further drying at 25 °C overnight as necessary. Once dried, sample particles were dissolved in DMSO with subsequent dilution in HPLC diluent to a final TA concentration of 0.2 mg/mL. Impurities were identified on the basis of the retention time of known compounds and quantified as percentage weight using validated response factors. The percentage free drug in each TA-ER ± local anesthetic preparation was assessed by analyzing the supernatant from the centrifugation step of the impurity sample preparation.

Particle Size Determination {#Sec6}
---------------------------

Particle size was evaluated using a Malvern Mastersizer 3000 Hydro MV Unit (Malvern, UK). A 0.1% v/v polysorbate 80 and water solution was used as the sample dispersant. Approximately 50 mg National Institute of Standards and Technology (NIST) traceable Glass Sphere Particle Size Standards (20--50 µm) were used for standard calibration and analysis. Following the 30-min incubation, the TA-ER ± local anesthetic mixtures were centrifuged, and particles harvested on a centrifuge filter. The solids were added to the particle sizer until the required light obscuration was achieved and then the samples were analyzed.

Optical Microscopy {#Sec7}
------------------

The impact of mixing local anesthetics with TA-ER with respect to particle aggregation or agglomeration was qualitatively assessed by light microscopy. A 1-mL aliquot of each TA-ER control and TA-ER + local anesthetic preparation was evaluated using an Olympus BH-2 microscope at ×100 magnification with digital image capture achieved using a Canon PowerShot G7 PC1210 equipped with a 58-mm microscope adapter. Some magnification variation occurred during image collection and processing, so no scale indications are provided. Because these images are for qualitative assessment the absolute scale of images was not critical to data interpretation.

Compliance with Ethical Guidelines {#Sec8}
----------------------------------

This article does not contain any studies with human participants or animal studies performed by any of the authors.

Results {#Sec9}
=======

Syringeability and pH Assays {#Sec10}
----------------------------

All samples passed the syringeability test, with no clogs observed (Table [1](#Tab1){ref-type="table"}).Table 1Syringeability and pH measurementSample^a^SyringeabilitypH (mean ± SD)ControlPass6.6 ± 0.3+ 5 mL diluentPass6.9 ± 0.1+ 5 mL lidocainePass6.4 ± 0.1+ 5 mL bupivacainePass6.4 ± 0.2+ 5 mL ropivacainePass6.2 ± 0.2+ 5 mL mixed local anestheticsPass6.3 ± 0.1*SD* standard deviation^a^*n* = 3 replicates per sample type

Summary data for pH determinations are provided in Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. Values ranged from pH 6.2 to 6.9. As expected, because the TA-ER diluent is not buffered for pH control, the suspension pH is slightly lowered in mixtures of TA-ER with local anesthetic. This reduction is minor, within 1 pH unit, and well within typical product specifications for a parenteral product \[[@CR33]\].Fig. 1Suspension pH of TA-ER ± local anesthetic combinations. *LA* local anesthetic, *TA*-*ER* extended-release triamcinolone acetonide

High-Performance Liquid Chromatography {#Sec11}
--------------------------------------

A summary of data is provided in Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. No statistically meaningful differences in product purity or percentage free drug were observed across all sample types. The largest individual impurity was the same species across all sample types and was in the range of typical product and method variability.Table 2Purity and free drug analysisSample^a^Purity (% ± SD)Largest individual impurity (% ± SD)Total impurities (% ± SD)Free drug (% ± SD)Control98.9 ± 0.30.40 ± 0.121.1 ± 0.30.1 ± 0.0+ 5 mL diluent98.9 ± 0.20.35 ± 0.051.1 ± 0.10.1 ± 0.0+ 5 mL lidocaine98.7 ± 0.00.45 ± 0.031.3 ± 0.00.1 ± 0.0+ 5 mL bupivacaine98.9 ± 0.20.38 ± 0.081.1 ± 0.20.1 ± 0.0+ 5 mL ropivacaine98.8 ± 0.00.41 ± 0.021.2 ± 0.00.1 ± 0.0+ 5 mL mixed local anesthetic98.8 ± 0.10.40 ± 0.061.2 ± 0.10.1 ± 0.0*SD* standard deviation^a^*n* = 3 replicates per sample typeFig. 2Suspension (**a**) and primary individual purity (**b**) of TA-ER ± local anesthetic combinations.*LA* local anesthetic,*TA-ER* extended-release triamcinolone acetonide

Particle Size Determination {#Sec12}
---------------------------

Particle size data are summarized in Table [3](#Tab3){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}. No statistically meaningful differences were observed for any of the volume distribution fractions measured. The greatest variability was observed in the D~90~ fraction, with maximum variability in the controls, indicating no effect from the local anesthetic solutions when mixed with TA-ER. The variability observed is consistent with typical method performance \[[@CR34]\].Table 3Particle size distribution resultsSample^a^Particle size distribution (µm) (mean ± SD)DV~10~DV~50~DV~90~Control23 ± 038 ± 164 ± 4+ 5 mL diluent22 ± 138 ± 167 ± 5+ 5 mL lidocaine22 ± 037 ± 061 ± 1+ 5 mL bupivacaine22 ± 037 ± 063 ± 1+ 5 mL ropivacaine22 ± 138 ± 064 ± 1+ 5 mL mixed local anesthetic22 ± 138 ± 164 ± 2*SD* standard deviation^a^*n* = 3 replicates per sample typeFig. 3Particle size distribution results.*LA* local anesthetic

Optical Microscopy {#Sec13}
------------------

Optical microscopy results are presented in Fig. [4](#Fig4){ref-type="fig"}. No differences in agglomeration or aggregation were observed with the addition of local anesthetic solutions.Fig. 4Qualitative microscopy results.*LA* local anesthetic

Discussion {#Sec14}
==========

In clinical practice, lidocaine, bupivacaine, and/or ropivacaine are commonly added to IA corticosteroid injection solutions, including TA \[[@CR6], [@CR7], [@CR16], [@CR19]--[@CR22], [@CR24]--[@CR26]\]. In this study, we assessed the impact of adding various local anesthetics to the injection suspension of TA-ER, a novel, extended-release formulation of TA. Physical and chemical compatibility of the mixture was assessed by measuring syringeability, pH, particle size, physical appearance, purity, and percentage free drug assays. Prior studies of local anesthetic absorption kinetics demonstrate rapid dissemination of drug from the injection site \[[@CR6], [@CR10]--[@CR13]\]. Therefore, the effects of local anesthetic on TA-ER molecules would be greatest during the process of preparing the injection solution. In this study, a 30-min incubation was used to provide ample time to observe any negative effects of local anesthetic on the TA-ER molecules and drug release.

Mixtures of local anesthetic solutions with reconstituted TA-ER did not demonstrate physical or chemical changes in the TA-ER formulation. These results are consistent with commonly used injection preparations for the treatment of OA and previous in vitro analyses of mixing steroid preparations and local anesthetic solutions \[[@CR6], [@CR17], [@CR24], [@CR25]\]. The addition of a local anesthetic to TA-ER preparations results in a 10-mL injection volume, which is consistent with the 5- to 10-mL IA injection volumes commonly used in clinical practice \[[@CR7], [@CR9], [@CR16], [@CR20]--[@CR22]\].

There were limitations to this study, including the evaluation of mixtures at only the 30-min time point after combination. The time limit of 30 min was based on the standard practice of reconstitution and preparation of corticosteroid solutions immediately prior to injection. According to the TA-ER instructions for use, the reconstituted TA-ER suspension can be stored within the vial for up to 4 h \[[@CR32]\]. However, once the TA-ER preparation is pulled into the syringe it should be immediately administered. This study did not assess TA-ER reconstitution in the local anesthetic solution, as TA-ER instructions for use specify using the product-specific diluent for proper wetting, dispersion, and dosing of TA-ER. TA-ER should not be reconstituted directly in local anesthetic solutions.

Conclusions {#Sec15}
===========

Adding local anesthetic to the TA-ER injection solution does not result in demonstrable physical or chemical changes, which is consistent with the clinical experience of adding local anesthetic solutions to other corticosteroid preparations.
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